Home News

First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Thu, 05/11/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
ROVI receives the European Commission’s approval of Okedi® as a treatment for...
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the European Commission has authorised the...
3 min
15/02/2022
Grant of partially reimbursable aid for the assessment of toxicity in...
  Madrid - January 28, 2022 Last May, ROVI signed a financing agreement with the Centre for Industrial Technological Development...
1 min
28/01/2022
ROVI recibe la opinión positiva del CHMP para Okedi® como tratamiento de la esquizofrenia
ROVI receives the positive opinion of the CHMP on Okedi® as a treatment for...
Laboratorios Farmacéuticos Rovi, a pan-European pharmaceutical company specializing and engaging in the research, development, contract...
4 min
17/12/2021